XML 46 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Segments of Business (Tables)
 3 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals
Financial information relating to our reportable operating segments and reconciliations to the condensed consolidated totals is as follows:
 
Quarter Ended June 30,
(In millions)
2018
 
2017
Revenues
 
 
 
U.S. Pharmaceutical and Specialty Solutions (1)
$
40,977

 
$
40,282

European Pharmaceutical Solutions (2)
6,935

 
6,382

Medical-Surgical Solutions (3)
1,703

 
1,533

Other
2,992

 
2,854

Total Revenues
$
52,607

 
$
51,051

 
 
 
 
Operating profit
 
 
 
U.S. Pharmaceutical and Specialty Solutions (4)
$
543

 
$
475

European Pharmaceutical Solutions (5)
(560
)
 
35

Medical-Surgical Solutions
93

 
108

Other (6)
114

 
17

Total
190

 
635

Corporate Expenses, Net
(123
)
 
(109
)
Interest Expense
(61
)
 
(68
)
Income from Continuing Operations Before Income Taxes
$
6

 
$
458

 
 
 
 
Revenues, net by geographic area
 
 
 
United States
$
42,890

 
$
42,093

Foreign
9,717

 
8,958

Total Revenues
$
52,607

 
$
51,051

(1)
Revenues derived from services represent less than 1% of this segment’s total revenues.
(2)
Revenues derived from services represent less than 10% of this segment’s total revenues.
(3)
Revenues derived from services represent less than 1% of this segment’s total revenues.
(4)
Our U.S. Pharmaceutical and Specialty Solutions segment operating profit for the first quarters of 2019 and 2018 includes $21 million in pre-tax credits and $26 million in pre-tax charges related to our last-in, first-out (“LIFO”) method of accounting for inventories. The LIFO inventory credit in the first quarter of 2019 was primarily due to lower full year expectations for net price increases compared to the same period a year ago. Operating profit for the first quarter of 2019 also includes $35 million of cash receipts for our share of antitrust legal settlements.
(5)
European Pharmaceutical Solutions segment’s operating profit for the first quarter of 2019 includes non-cash goodwill impairment charges (pre-tax and after-tax) of $570 million.
(6)
The first quarter of 2019 operating profit for Other includes pre-tax restructuring charges of $38 million (pre-tax and after-tax) primarily associated with the closure of retail pharmacy stores within our Canadian business. Operating profit for the first quarter of 2019 also includes a pre-tax gain from escrow settlement of $97 million representing certain indemnity and other claims related to our 2017 third quarter acquisition of Rexall Health. Operating profit for the first quarter of 2018 includes a pre-tax gain of $37 million (after-tax gain of $22 million) upon the finalization of net working capital and other adjustments related to the contribution of the majority of our Core MTS Business to Change Healthcare in the fourth quarter of 2017.